1. Huang P, Wang D, Su Y, Huang W, Zhou Y, Cui D, et al. Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug–Drug Conjugate for Cancer Therapy. Journal of the American Chemical Society. 2014;136(33):11748-56.
2. Zhang Y, Yang C, Wang W, Liu J, Liu Q, Huang F, et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Scientific reports. 2016;6:21225.
3. Zou P, Song J, Jiang B, Pei F, Chen B, Yang X, et al. Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse. International Journal of Clinical and Experimental Pathology. 2014;7(8):4607-16.
4. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Advanced drug delivery reviews. 2009;61(13):1203-13.
5. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug discovery today. 2012;17(17-18):1044-52.
6. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32(32):8281-90.
7. Wang W, Xi M, Duan X, Wang Y, Kong F. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. International journal of nanomedicine. 2015;10:3737-50.
8. Muthoosamy K, Abubakar IB, Bai RG, Loh HS, Manickam S. Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment. Scientific reports. 2016;6:32808.
9. Wang J, Wang F, Li F, Zhang W, Shen Y, Zhou D, et al. A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells †Electronic supplementary information (ESI) available: The synthesis procedure of Biotin–PEG–PCDA and the experimental results of MTT. See DOI: 10.1039/c5tb02450a Click here for additional data file. Journal of Materials Chemistry B, Materials for Biology and Medicine. 2016;4(17):2954-62.
10. Baek JS, Cho CW. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells. Oncotarget. 2017;8(18):30369-82.
11. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365-83.
12. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today. 2012;17(1-2):71-80.
13. Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC. Therapeutic Applications of Curcumin Nanoformulations. The AAPS journal. 2015;17(6):1341-56.
14. Yang X, Li Z, Wang N, Li L, Song L, He T, et al. Curcumin-Encapsulated Polymeric Micelles Suppress the Development of Colon Cancer In Vitro and In Vivo. Scientific Reports. 2015;5:10322.
15. Bagheri A, Seang Chu, B , Yaakob,H. Niosomal Drug Delivery Systems: Formulation, Preparation and Applications. World Applied Sciences Journal 2014;32(8):1671-85.
16. Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. Niosomes from 80s to present: The state of the art. Advances in Colloid and Interface Science. 2014;205:187-206.
17. Mohamed HB, El-Shanawany SM, Hamad MA, Elsabahy M. Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities. Scientific Reports. 2017;7(1):6340.
18. Ojeda E, Puras G, Agirre M, Zarate J, Grijalvo S, Pons R, et al. Niosomes based on synthetic cationic lipids for gene delivery: the influence of polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells. Organic & Biomolecular Chemistry. 2015;13(4):1068-81.
19. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics. 1998;172(1):33-70.
20. Alemi A, Zavar Reza J, Haghiralsadat F, Zarei Jaliani H, Haghi Karamallah M, Hosseini SA, et al. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. Journal of Nanobiotechnology. 2018;16(1):28.
21. Alemi A F, M., Haghi Karamallah, M., Farrokhifar, M., Entezari Nasab, Z., Farrokhifar,. A A novel Paclitaxel loaded Noisome: Preparation, Characterization and Cytotoxicity Assessment against human prostate cancer. Cancer Press. 2017;3(3):103-12.
22. Alemi A F, M., Haghi Karamallah, M., Farrokhifar, M., Entezari Nasab, Z., Farrokhifar, A. Evaluation of the efficacy of Niosomal Curcumin Nanoformulation in Cancer therapy. Cancer Press. 2017;3((3):):77-85.
23. Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: An efficient carrier for cancer multi-drug delivery. Materials Science and Engineering: C. 2015;56:393-400.
24. Alemi A, Farrokhifar M, Zare-Zardini H, Haghi Karamallah M. A Comparison between the Anticancer Activities of Free Paclitaxel and Paclitaxel-Loaded Niosome Nanoparticles on Human Acute Lymphoblastic Leukemia Cell Line Nalm-6. Iranian journal of Pediatric Hematology and Oncology. 2018;8(3):153-60.
25. Kassem MA, El-Sawy HS, Abd-Allah FI, Abdelghany TM, El-Say KM. Maximizing the Therapeutic Efficacy of Imatinib Mesylate-Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design. Journal of pharmaceutical sciences. 2017;106(1):111-22.
26. Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. International Journal of Pharmaceutics. 2015;493(1):285-94.
27. Tavano L, Muzzalupo R, Picci N, de Cindio B. Co-encapsulation of antioxidants into niosomal carriers: Gastrointestinal release studies for nutraceutical applications. Colloids and Surfaces B: Biointerfaces. 2014;114:82-8.
28. Zare-Zardini H, Alemi A, Taheri-Kafrani A, Hosseini SA, Soltaninejad H, Hamidieh AA, et al. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study. Drug Des Devel Ther. 2020;14:3315-24.
29. El-Hamid ESA, Gamal-Eldeen AM, Sharaf Eldeen AM. Liposome-coated nano doxorubicin induces apoptosis on oral squamous cell carcinoma CAL-27 cells. Archives of Oral Biology. 2019;103:47-54.
30. Gumulec J, Fojtu M, Raudenska M, Sztalmachova M, Skotakova A, Vlachova J, et al. Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages. Int J Mol Sci. 2014;15(12):22960-77.
31. Zhu C, He L, Zhou X, Nie X, Gu Y. Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors. Oncol Rep. 2016;35(3):1318-28.
32. Asoodeh A, Alemi A, Heydari A, Akbari J. Purification and biochemical characterization of an acidophilic amylase from a newly isolated Bacillus sp. DR90. Extremophiles : life under extreme conditions. 2013;17(2):339-48.
33. Ramakers C, Ruijter JM, Deprez RHL, Moorman AFM. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neuroscience Letters. 2003;339(1):62-6.
34. Ruijter JM, Lefever S, Anckaert J, Hellemans J, Pfaffl MW, Benes V, et al. RDML-Ninja and RDMLdb for standardized exchange of qPCR data. BMC bioinformatics. 2015;16:197.
35. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic acids research. 2009;37(6):e45.
36. De Pascale C, Graham V, Fowkes RC, Wheeler-Jones CP, Botham KM. Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants: modulation by the fatty acid composition of the particles. The FEBS journal. 2009;276(19):5689-702.
37. Malaponte G, Signorelli SS, Bevelacqua V, Polesel J, Taborelli M, Guarneri C, et al. Increased Levels of NF-kB-Dependent Markers in Cancer-Associated Deep Venous Thrombosis. PloS one. 2015;10(7):e0132496.
38. Saha D, Koli S, Patgaonkar M, Reddy KV. Expression of hemoglobin-alpha and beta subunits in human vaginal epithelial cells and their functional significance. PloS one. 2017;12(2):e0171084.
39. Ruttala HB, Ko YT. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids and Surfaces B: Biointerfaces. 2015;128:419-26.
40. Devassy JG, Nwachukwu ID, Jones PJH. Curcumin and cancer: barriers to obtaining a health claim. Nutrition Reviews. 2015;73(3):155-65.
41. Guan F, Ding Y, Zhang Y, Zhou Y, Li M, Wang C. Curcumin Suppresses Proliferation and Migration of MDA-MB-231 Breast Cancer Cells through Autophagy-Dependent Akt Degradation. PloS one. 2016;11(1):e0146553.
42. Liu D, Chen Z. The Effect of Curcumin on Breast Cancer Cells. J Breast Cancer. 2013;16(2):133-7.
43. Shehzad A, Lee YS. Molecular mechanisms of curcumin action: Signal transduction. BioFactors. 2013;39(1):27-36.
44. Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PloS one. 2014;9(4):e95588.
45. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Molecular pharmaceutics. 2009;6(3):928-39.
46. Bava SV, Sreekanth CN, Thulasidasan AKT, Anto NP, Cheriyan VT, Puliyappadamba VT, et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. The International Journal of Biochemistry & Cell Biology. 2011;43(3):331-41.
47. Liu T-Y, Tan Z-J, Jiang L, Gu J-F, Wu X-S, Cao Y, et al. Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells. Cancer Cell Int. 2013;13(1):64-.